Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine® SD) in patients with haemophilia B undergoing surgical intervention: A single institution retrospective analysis

Haemophilia

Volumn 17, Issue 1, 2011, Pages

  Quon, D V K ^a   Logan, L ^a  

^a JOINT REPLACEMENT INSTITUTE   (United States)

Author keywords

Coagulation; Factor IX; Haemophilia B; Haemostasis; Plasma derived FIX; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; GENERAL ANESTHESIA; HEMOPHILIA B; HEMOSTASIS; HUMAN; LENGTH OF STAY; OPERATION DURATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; FACTOR IX; FEMALE; HEMOPHILIA B; HEMOSTASIS, SURGICAL; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTOPERATIVE CARE; PREOPERATIVE CARE; RETROSPECTIVE STUDIES;

EID: 79951897643     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02354.x     Document Type: Article

References (28)

1. Biggs R, Douglas AS, MacFarlane RG, Dacien JV, Pitney WR, Merskey C. Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952; 2: 1378-82.
2. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
3. Mishra V, Tjonnfjord GE, Paus AC, Vaaler S. Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure. Haemophilia 2002; 8: 809-14.
4. United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
5. Bardin JM, Sultan Y. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion 1990; 30: 441-3.
6. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
7. Santagostino E, Mannucci PM, Gringeri A et al. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery. Thromb Haemost 1994; 71: 737-40.
8. Goldsmith JC, Kasper CK, Blatt PM et al. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate. Am J Hematol 1992; 40: 210-5.
9. Evans G, Collett M, Came N, Lloyd J, Powell L, Street A. MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study. Haemophilia 2002; 8: 635-8.
10. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5: 96-100.
11. Hoots WK, Leissinger C, Stabler S et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. Haemophilia 2003; 9: 164-72.
12. Djulbegovic B, Marasa M, Pesto A et al. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol 1996; 51: 168-70.
13. Zakarija A. Factor IX replacement in surgery and prophylaxis. Blood Coagul Fibrinolysis 2004; 15(Suppl. 2): S5-7.
14. Gascoigne EW, Dash CH, Harman C, Wilmot D. A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate. Pharmacoepidemiol Drug Saf 2004; 13: 187-95.
15. Trzeciak S, Dellinger RP. Other supportive therapies in sepsis: an evidence-based review. Crit Care Med 2004; 32: S571-7.
16. Kuhl DA. Current strategies for managing the patient with sepsis. Am J Health Syst Pharm 2002; 59(Suppl. 1): S9-13.
17. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA 1986; 256: 744-9.
18. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
19. Cheadle WG, Branson RD, Franklin GA. Hemorrhagic risk and blood components. In: Bland KI, Callery MP, Clagett GP, Jones DB eds. Mastery of Surger. Philadelphia, PA: Lippincot Williams & Wilkins, 2001: 87-100.
20. Johansson T, Engquist M, Pettersson LG, Lisander B. Blood loss after total hip replacement: a prospective randomized study between wound compression and drainage. J Arthroplasty 2005; 20: 967-71.
21. Lemay E, Guay J, Cote C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. Can J Anaesth 2004; 51: 31-7.
22. Tidermark J, Blomfeldt R, Ponzer S, Soderqvist A, Tornkvist H. Primary total hip arthroplasty with a Burch-Schneider antiprotrusion cage and autologous bone grafting for acetabular fractures in elderly patients. J Orthop Trauma 2003; 17: 193-7.
23. Slappendel R, Weber EW, Benraad B, Dirksen R, Bugter ML. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol 2002; 19: 829-31.
24. Harley BJ, Beaupre LA, Jones CA, Cinats JG, Guenther CR. The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: a pilot study. Can J Surg 2002; 45: 185-90.
25. Aznar JA, Cabrera N, Matysiak M et al. Pharmacokinetic study of a high-purity factor IX concentrate (factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. Haemophilia 2009; 15: 1243-8.
26. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
27. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35: 33-8.
28. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.